Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley Buys 40,000 Shares

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley purchased 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was bought at an average price of C$1.88 per share, for a total transaction of C$75,072.00.

Cardiol Therapeutics Stock Up 2.4 %

Cardiol Therapeutics stock opened at C$1.95 on Wednesday. The stock has a market capitalization of C$136.27 million, a price-to-earnings ratio of -4.43 and a beta of 0.70. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07. The stock has a 50 day moving average of C$2.41 and a two-hundred day moving average of C$2.73. Cardiol Therapeutics Inc. has a twelve month low of C$1.07 and a twelve month high of C$4.26.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.